# US 2003/0225052 A1 · Analogs of terpene trilactones from Ginkgo biloba and related compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225052 A1
- Document ID: US20030225052A1
- Status: Published application
- Kind: A1
- Application number: 10/401,931
- Filed: 2003-03-28
- Published: 2003-12-04
- Earliest claimed: 2002-03-29
- Assignees: The Trustees of Columbia University in the City of New York
- Inventors: Kristian Stromgaard; Makiko Suehiro; Koji Nakanishi; Stine B. Vogensen
- Web page: https://patentgrep.com/patent/US20030225052A1

## CPC

- C07D 493/20: Spiro-condensed systems
- C07D 493/22: in which the condensed system contains four or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The subject invention provides compounds having the structure: 1 wherein R1 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; R2 is H, OH, a photoactivatable moiety, a fluorescent-moiety, or a radioactive moiety; R3 is H or OH; R4 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; and wherein at least one of R1, R2, R3, or R4 is a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety, or an optically pure enantiomer of the compound or wherein R1 is H or OH; R2 is H, OH, halogen, unsubstituted or substituted, straight or branched (C1-C5) alkyl group, (C2-C5) alkenyl, or a (C2-C5) alkynyl, (C1-C5) alkoxy, (C2-C5) alkenyloxy, or (C2-C5) alkynyloxy, —N3, —COR5, —CONR5R6, —CO2R5, —OCOR5, —NH(OH), —NR5R6, —NHCOR5, —N(OH)COR5, —CH2OR5, —OCH2CO2R5, —CH2SR5, —CH2NR5R6, —SR5, —OSR5, or —NR5SO2R6, where R5 and R6 are each independently hydrogen, substituted or unsubstituted (C1-C5) alkyl, (C2-C5) alkenyl, or (C2-C5) alkynyl, or a cycloalkyl or aryl group having 3 to 10 carbon atoms; R3 is H or OH; R4 is H, (C1-C10) alkyl, (C1-C10) alkenyl, (C1-C10) alkynyl, -A-Ar, -A-Z-Ar, —SO2—Ar, or -A-NR5, or —R7, where A, Z and Ar are as defined herein, and the use of the compounds for detecting or identifying a receptor which binds the compounds of the invention or for treating a PAF associated condition in a subject.

## Claims

### Claim 1

A compound having the structure:
34
wherein R1 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety;
wherein R2 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety;
wherein R3 is H or OH;
wherein R4 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; and
wherein at least one of R1, R2, R3, or R4 is a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety,
or an optically pure enantiomer of the compound.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is a fluorescent moiety and each of R2 and R4 is H or OH.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R2 is a fluorescent moiety or a radioactive moiety and each of R1 and R4 is H or OH.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R4 is a photoactivatable moiety or a radioactive moiety and each of R1 and R2 is H or OH.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the photoactivatable moiety is a phenylazide, a purine or pyrimidine azides, a diazoacetate, a diazoketone, a nitrobenzene, or an aryldiazonium salt.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the photoactivatable moiety is benzophenone, trifluoromethyldiazirine tetrafluorophenyl, 8-azidoadenosine, 2-azidoadenosine, or 3H,3-aryldiazirine.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the fluorescent moiety is a fluorescent amine.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the fluorescent moiety is 5-(dimemethylamino)naphthalene-sulfonyl (dansyl), 1-(Bromoacetyl)pyrene, 3-Bromoacetyl-7-diethylaminocoumarin, 3-Bromomethyl-6,7-dimethoxycoumarin, 8-Bromomethyl-4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene, 3-Bromomethyl-6,7-dimethoxy-1-methyl-2(1H)-quinoxazolinone, 6-Bromoacetyl-2-dimethylaminonaphthalene, or 4-(9-Anthroyloxy)phenacyl bromide.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the radioactive moiety is 11C, 13N, 15O, 3H or 18F.

### Claim 10 (depends on 6)

The compound of claim 6, wherein the photoactivatable moiety is benzophenone, trifluoromethyldiazirine or tetrafluorophenyl.

### Claim 11 (depends on 8)

The compound of claim 8, wherein the fluorescent moiety is 5-(dimemethylamino)naphthalene-sulfonyl.

### Claim 12 (depends on 9)

The compound of claim 9, wherein the radioactive moiety is 18F, 11C or 3H.

### Claim 13 (depends on 1)

The compound of claim 1 having the structure:
35

### Claim 14 (depends on 13)

The compound of claim 13, wherein R1 is —O-5-(dimemethylamino)naphthalene-sulfonyl.

### Claim 15 (depends on 13)

The compound of claim 13, wherein R2 is —O-5-(dimemethylamino)naphthalene-sulfonyl.

### Claim 16 (depends on 13)

The compound of claim 13, wherein R2 is —11CH3.

### Claim 17 (depends on 13)

The compound of claim 13, wherein R2 is —CH2CH218F.

### Claim 18 (depends on 1)

The compound of claim 1, wherein R2 is 18F.

### Claim 19 (depends on 13)

The compound of claim 13, wherein R2 is 3H.

### Claim 20 (depends on 13)

The compound of claim 13, wherein R4 is a benzophenone moiety.

### Claim 21 (depends on 13)

The compound of claim 13, wherein R4 is a trifluoromethyldiazirine moiety.

### Claim 22 (depends on 13)

The compound of claim 13, wherein R4 is a tetrafluorophenyl azide moiety.

### Claim 23 (depends on 13)

The compound of claim 13, wherein R4 is —11CH3.

### Claim 24 (depends on 13)

The compound of claim 13, wherein R4 is —CH2CH218F.

### Claim 25 (depends on 14)

The compound of claim 14, having the structure:
36

### Claim 26 (depends on 15)

The compound of claim 15 having the structure:
37

### Claim 27 (depends on 18)

The compound of claim 18 having the structure:
38

### Claim 28 (depends on 19)

The compound of claim 19 having the structure:
39

### Claim 29 (depends on 23)

The compound of claim 23 having the structure:
40

### Claim 30 (depends on 24)

The compound of claim 24 having the structure:
41

### Claim 31 (depends on 13)

The compound of claim 13 having the structure:
42

### Claim 32 (depends on 20)

The compound of claim 20 having the structure:
43
wherein R2 is H or OH.

### Claim 33 (depends on 21)

The compound of claim 21 having the structure:
44
wherein R2 is H or OH.

### Claim 34 (depends on 22)

The compound of claim 22 having the structure:
45
wherein R2 is H or OH.

### Claim 35

A compound having the structure:
46
wherein R1 is H or OH,
wherein R2 is H, OH, halogen, unsubstituted or substituted, straight or branched (C1-C5) alkyl group, (C2-C5) alkenyl, or a (C2-C5) alkynyl, (C1-C5) alkoxy, (C2-C5) alkenyloxy, or (C2-C5) alkynyloxy, —N3, —COR5, —CONR5R6, —CO2R5, —OCOR5, —NH(OH), —NR5R6, —NHCOR5, —N(OH)COR5, —CH2OR5, —OCH2CO2R5, —CH2SR5, —CH2NR5R6, —SR5, —OSR5, or —NR5SO2R6,
where R5 and R6 are each, independently, hydrogen, substituted or unsubstituted (C1-C5) alkyl, (C2-C5) alkenyl, or (C2-C5) alkynyl, or a cycloalkyl or aryl group having 3 to 10 carbon atoms;
wherein R3 is H or OH; and
wherein R4 is H, OH, (C1-C10) alkyl, (C2-C10) alkenyl, (C2-C10) alkynyl, -A-Ar, -A-Z-Ar, —SO2—Ar, or -A-NR6, or —R6,
where A is (C1-C8) alkyl-, (C2-C8) alkenyl, (C2-C8)alkynyl, which is unsubstituted or substituted by a straight or branched alkyl chain group having 1 to 5 carbon atoms;
Z is carbon, oxygen, sulfur or nitrogen;
Ar is a phenyl group, a pyridyl group, a naphthyl group, a pyrimidyl group, or a quinolyl group, each of which may contain heteroatoms and may be unsubstituted or substituted by one to five substituents selected from the group consisting of hydrogen, halogen, a hydroxy group, a carboxylic acid group, substituted or unsubstituted (C1-C10) alkyl, (C2-C10) alkenyl, (C2-C10) alkynyl, (C1-C10) haloalkyl, (C1-C10) alkoxy, (C2-C10) alkenyloxy, (C2-C10) alkynyloxy, (C1-C10) haloalkoxy, a phenyl group, a phenoxy group, an aralkyl group, an aralkyloxy group, a substituted phenyl group, a substituted phenoxy group, a substituted aralkyl group, a substituted aralkyloxy group, —COR6, —CONR6R6, —CO2R6, —NHCOR6, —NH(OH), —N(OH)COR6, —CH2OR6, —OCH2CO2R6, —CH2SR6, —CH2NR6R6, —SR6, —OSR6, —NR6R6, —NR6SO2R6,
where R6 is hydrogen, (C1-C10) alkyl, (C3-C10) cycloalkyl, —SCX3 in which X is a halogen, —CN, —NO2 or -Z-A-Z′- in which Z and A are as defined above and Z′ represents carbon, oxygen, sulfur, or nitrogen;
or an optically pure enantiomer, or a tautomer, or a salt of the compound.

### Claim 36 (depends on 35)

The compound of claim 35 having the structure:
47
wherein R2 is Cl, F, OH, a substituted or unsubstituted, straight or branched (C1-C5) alkyl, (C2-C5) alkenyl, (C2-C5) alkynyl, (C1-C5) alkoxy, (C2-C5) alkenyloxy, or (C2-C5) alkynyloxy, —N3, —COR5, —CONR5R6, —CO2R5, —OCOR5, —NH(OH), —NR5R6, —NHCOR5, —N(OH)COR5, —CH2OR5, —OCH2CO2R5, —CH2SR5, —CH2NR5R6, —SR5, —OSR5, or —NR5SO2R6,
where R5 and R6 are each, independently, hydrogen, substituted or unsubstituted (C1-C5) alkyl, (C2-C5) alkenyl, or (C2-C5) alkynyl, or a cycloalkyl or aryl group having 3 to 10 carbon atoms;
wherein R4 is H or R8;
wherein R4 is R8 when R2 is F;
wherein R8 is (C1-C10) alkyl, (C2-C10) alkenyl, (C2-C10) alkynyl, -A-Ar, -A-Z-Ar, —SO2—Ar, or -A-NR6,
where A is an unsubstituted, straight chain (C1-C5)alkyl, (C2-C5) alkenyl, (C2-C5) alkynyl;
Z is carbon, oxygen, sulfur or nitrogen;
Ar is a phenyl group, a pyridyl group, a naphthyl group, a pyrimidyl group, or a quinolyl group, each of which may contain heteroatoms and may be unsubstituted or substituted by one to five substituents selected from the group consisting of hydrogen, halogen, hydroxy, substituted or unsubstituted (C1-C10) alkyl, (C2-C10) alkenyl, (C2-C10) alkynyl, (C1-C10) alkoxy, (C2-C10) alkenyloxy, (C2-C10) alkynyloxy, phenyl, phenoxy, aralkyl, or aralkyloxy, —COR6, —CONR6R6, —CO2R6, —NHCOR6, —NH(OH), —N(OH)COR6, —CH2OR6, —OCH2CO2R6, —CH2SR6, —CH2NR6R6, —SR6, —OSR6, —NR6R6, or —NR6SO2R6,
where R6 is hydrogen, (C1-C10) alkyl, (C3-C10) cycloalkyl, —SCX3 in which X is a halogen, —CN, —NO2 or -Z-A-Z′- in which Z and A are as defined above and Z′ represents carbon, oxygen, sulfur, or nitrogen,
or an optically pure enantiomer, or a tautomer, or a salt of the compound.

### Claim 37 (depends on 36)

The compound of claim 36, wherein R4 is H or -A-Ar.

### Claim 38 (depends on 37)

The compound of claim 37, wherein R4 is H or —CH2C6H5.

### Claim 39 (depends on 36)

The compound of claim 36, wherein R2 is OH, Cl, —N3, —OCOR3, or —NR3R4.

### Claim 40 (depends on 36)

The compound of claim 36, wherein R2 is OH, Cl, —OCOCH3, —OCOCH2C6H5, —N3, —NH2, —NHCH3, —NHCH2CH3.

### Claim 41 (depends on 36)

The compound of claim 36, wherein R2 is OH, Cl, —OCOCH3, —OCOCH2C6H5, —N3, —NH2, —NHCH3, —NHCH2CH3; and wherein R4 is H or —CH2C6H5.

### Claim 42 (depends on 35)

The compound of claim 35, wherein R1 is OH, R2 is F, R3 is OH, and R4 is H.

### Claim 43 (depends on 36)

The compound of claim 36, wherein R2 is Cl, and R4 is H.

### Claim 44 (depends on 36)

The compound of claim 36, wherein R2 is —N3, and wherein R4 is H.

### Claim 45 (depends on 36)

The compound of claim 36, wherein R2 is —NHCH3, and wherein R4 is H.

### Claim 46 (depends on 36)

The compound of claim 36, wherein R2 is —NHCH2CH3, and wherein R4 is H.

### Claim 47 (depends on 36)

The compound of claim 36, wherein R2 is —OCOCH2C6H5, and wherein R4 is H.

### Claim 48 (depends on 36)

The compound of claim 36, wherein R2 is F, and wherein R4 is —CH2C6H5.

### Claim 49 (depends on 36)

The compound of claim 36, wherein R2 is Cl, and wherein R4 is —CH2C6H5.

### Claim 50 (depends on 36)

The compound of claim 36, wherein R2 is H, and wherein R4 is —CH2C6H5.

### Claim 51 (depends on 36)

The compound of claim 36, wherein R2 is OH, and wherein R4 is —CH2C6H5.

### Claim 52 (depends on 35)

The compound of claim 35 having the structure:
48
wherein R1 is H or OH;
wherein R2 is H, F, Br, unsubstituted or substituted, straight or branched (C1-C5) alkyl group, (C2-C5) alkenyl, or a (C2-C5) alkynyl;
wherein R3 is H or OH; and
wherein R4 is H, -A-Ar, -A-Z-Ar, —SO2—Ar, or -A-NR6, or —R6,
where A is an alkylene group having 1 to 8 carbon atoms, which is unsubstituted or substituted by a straight or branched alkyl chain group having 1 to 5 carbon atoms;
Z is carbon, oxygen, sulfur or nitrogen;
Ar is a phenyl group, a pyridyl group, a naphthyl group, a pyrimidyl group, or a quinolyl group, each of which may contain heteroatoms and may be unsubstituted or substituted by one to five substituents selected from the group consisting of hydrogen, halogen, a hydroxy group, a carboxylic acid group, (C1-C10) alkyl, (C2-C10) alkenyl, (C2-C10) alkynyl, a (C1-C10) haloalkyl, an (C1-C10) alkoxy, an (C2-C10) alkenyloxy, an (C2-C10) alkynyloxy, a (C1-C10) haloalkoxy, a phenyl group, a phenoxy group, an aralkyl group, an aralkyloxy group, a substituted phenyl group, a substituted phenoxy group, a substituted aralkyl group, a substituted aralkyloxy group, —COR6, —CONR6R6, —CO2R6, —NHCOR6, —NH(OH), —N(OH)COR6, —CH2OR6, —OCH2CO2R6, —CH2SR6, —CH2NR6R6, —SR6, —OSR6, —NR6R6, —NR6SO2R6,
where R6 is hydrogen, (C1-C10) alkyl, (C3-C10) cycloalkyl, —SCX3 in which X is a halogen, —CN, —NO2 or -Z-A-Z′- in which Z and A are as defined above and Z′ represents carbon, oxygen, sulfur, or nitrogen,
or an optically pure enantiomer, or a salt of the compound.

### Claim 53 (depends on 52)

The compound of claim 52, wherein R2 is F.

### Claim 54 (depends on 35)

The compound of claim 35, having the structure:
49
wherein R1 is H, or OH;
wherein R2 is H, OH, F, Br, unsubstituted or substituted, straight or branched (C1-C5) alkyl, (C2-C5) alkenyl, or (C2-C5) alkynyl;
wherein R3 is H or OH; and
wherein R4 is H, OH, -A-Ar, -A-Z-Ar, —SO2—Ar, or -A-NR5, or —R6,
where A is an (C1-C8) alkyl group, which is unsubstituted or substituted by a straight or branched (C1-C5) alkyl chain;
Z is carbon, oxygen, sulfur or nitrogen;
Ar is a phenyl group, a pyridyl group, a naphthyl group, a pyrimidyl group, or a quinolyl group, each of which may contain heteroatoms and may be unsubstituted or substituted by one to five substituents selected from the group consisting of hydrogen, halogen, a hydroxy group, a carboxylic acid group, (C1-C10) alkyl, (C2-C10) alkenyl, (C2-C10) alkynyl, (C1-C10) haloalkyl, (C1-C10) alkoxy, (C2-C10) alkenyloxy, (C2-C10) alkynyloxy, (C1-C10) haloalkoxy, a phenyl group, a phenoxy group, an aralkyl group, an aralkyloxy group, a substituted phenyl group, a substituted phenoxy group, a substituted aralkyl group, a substituted aralkyloxy group, —COR5, —COR6, —CONR5R6, —CO2R5, —NHCOR5, —NH(OH), —N(OH)COR5, —CHOR5, —OCH2CO2R5, —CH2SR5, —CH2NR5R6, —SR5, —OSR5, —O2NR5R6, —NR5R6, —NR5SO2R6,
in which R5 and R6 are the same or different and each is hydrogen, (C1-C10) alkyl or a (C3-C10) cycloalkyl, —SCX3 in which X is a halogen, —CN, —NO2 or -Z-A-Z′- in which Z and A are as defined above and Z′ represents carbon, oxygen, sulfur, or nitrogen,
or an optically pure enantiomer, or a salt of the compound.

### Claim 55 (depends on 54)

The compound of claim 54, wherein R2 is F.

### Claim 56

A compound having the structure:
50
wherein R4 is a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety.

### Claim 57 (depends on 56)

The compound of claim 56, wherein the photoactivatable moiety is a phenylazide, a purine or pyrimidine azides, a diazoacetate, a diazoketone, a nitrobenzene, or an aryldiazonium salt.

### Claim 58 (depends on 56)

The compound of claim 56, wherein the photoactivatable moiety is benzophenone, trifluoromethyldiazirine tetrafluorophenyl, 8-azidoadenosine, 2-azidoadenosine, or 3H,3-aryldiazirine.

### Claim 59 (depends on 56)

The compound of claim 56, wherein the fluorescent moiety is a fluorescent amine.

### Claim 60 (depends on 56)

The compound of claim 56, wherein the fluorescent moiety is 5-(dimemethylamino)naphthalene-sulfonyl (dansyl), 1-(Bromoacetyl)pyrene, 3-Bromoacetyl-7-diethylaminocoumarin, 3-Bromomethyl-6,7-dimethoxycoumarin, 8-Bromomethyl-4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene, 3-Bromomethyl-6,7-dimethoxy-l-methyl-2(1H)-quinoxazolinone, 6-Bromoacetyl-2-dimethylaminonaphthalene, or 4-(9-Anthroyloxy)phenacyl bromide.

### Claim 61 (depends on 55)

The compound of claim 55, wherein the radioactive moiety is 18F 11C, 3H.

### Claim 62

A compound having the structure:
51
wherein R4 is H, OH, -A-Ar, -A-Z-Ar, —SO2—Ar, or -A-NR5, or —R6,
where A is a (C1-C8) alkyl group, which is unsubstituted or substituted by a straight or branched (C1-C10) alkyl chain;
Z is carbon, oxygen, sulfur or nitrogen;
Ar is a phenyl group, a pyridyl group, a naphthyl group, a pyrimidyl group, or a quinolyl group, each of which may contain heteroatoms and may be unsubstituted or substituted by one to five substituents selected from the group consisting of hydrogen, halogen, a hydroxy group, a carboxylic acid group, (C1-C10) alkyl, (C2-C10) alkenyl, (C2-C10) alkynyl, (C1-C10) haloalkyl, (C1-C10) alkoxy, (C2-C10) alkenyloxy, (C2-C10) alkynyloxy, (C1-C10) haloalkoxy, a phenyl group, a phenoxy group, an aralkyl group, an aralkyloxy group, a substituted phenyl group, a substituted phenoxy group, a substituted aralkyl group, a substituted aralkyloxy group, —COR5, —COR6, —CONR5R6, —CO2R5, —NHCOR5, —NH(OH), —N(OH)COR5, —CHOR5, —OCH2CO2R5, —CH2SR5, —CH2NR5R6, —SR5, —OSR5, —O2NR5R6, —NR5R6, —NR5SO2R6,
in which R5 and R6 are the same or different and each is hydrogen, (C1-C10) alkyl or a (C3-C10) cycloalkyl group, —SCX3 in which X is a halogen, —CN, —NO2 or -Z-A-Z′- in which Z and A are as defined above and Z′ represents carbon, oxygen, sulfur, or nitrogen,
or an optically pure enantiomer, or a salt of the compound.

### Claim 63 (depends on 35, 36, 52, 54, 55, 62)

The compound of claim 35, 36, 52, 54, 55 or 62, wherein if any group is substituted, the substituent is halogen, hydroxyl, straight chain (C1-C5)alkyl, branched chain (C3-C5)alkyl, (C3-C10)cycloalkyl, straight chain(C1-C5)alkylcarbonyloxy, branched chain (C3-C5) alkylcarbonyloxy, arylcarbonyloxy, straight chain(C1-C5)alkoxycarbonyloxy, branched chain (C3-C5) alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, straight chain(C1-C5)alkylcarbonyl, branched chain (C3-C5)alkylcarbonyl, straight chain (C1-C5)alkoxycarbonyl, branched chain (C3-C5)alkoxycarbonyl, aminocarbonyl, straight chain (C1-C5)alkylthiocarbonyl, branched chain (C3-C5)alkylthiocarbonyl, straight chain (C1-C5)alkoxyl, branched chain (C1-C5)alkoxyl, phosphate, phosphonate, cyano, amino, straight chain (C1-C5)alkylamino, branched chain (C3-C5)alkylamino, straight chain (C1-C5)dialkylamino, branched chain (C3-C5)dialkylamino, arylamino, diarylamino, straight chain (C1-C5)alkylarylamino, branched chain (C3-C5)alkylarylamino, acylamino, straight chain (C1-C5) alkylcarbonylamino, branched chain (C3-C5) alkylcarbonylamino, arylcarbonylamino, carbamoyl, ureido, amidino, imino, sulfhydryl, straight chain (C1-C5)alkylthio, branched chain (C3-C5) alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, azido, 4-10 membered heterocyclyl, straight chain (C1-C30)alkylaryl, branched chain (C3-C30)alkylaryl, or an aromatic or 5-6 membered heteroaromatic moiety, which substituent may be further substituted by any of the above.

### Claim 64 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The pharmaceutically acceptable salt of the compound of any one of claims 35-55, wherein the salt is the chloride, mesylate, maleate, fumarate, tartarate, hydrochloride, hydrobromide, esylate, p-toluenesulfonate, benzoate, acetate, phosphate and sulfate salts.

### Claim 65 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 62, 64)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 35-55, 62 or 64, and a pharmaceutically acceptable carrier.

### Claim 66 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 62, 64)

A process for the manufacture of a pharmaceutical composition comprising admixing the compound of any one of claims 35-55, 62 or 64 with a pharmaceutically acceptable carrier.

### Claim 67 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 62, 64)

A method of inhibiting activation of the platelet-activating factor receptor (PAFR) which comprises contacting the PAFR with a compound of any one of claims 35-55, 62 or 64 so as to thereby inhibit activation of the PAFR.

### Claim 68 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 62, 64)

A method of treating a platelet-activating factor (PAF) associated condition in a subject comprising administering to the subject an amount of the compound of any one of claims 35-55, 62 or 64 effective to treat the PAF-associated disease.

### Claim 69 (depends on 68)

The method of claim 68, wherein the PAF-associated condition is a neurodegenerative disease, Alzheimer's disease, senile dementia, stroke, nerve cell damage due to ischemia, asthma, abnormal blood clot formation, endotoxic shock, myocardial ischemia or hyperacute rejection arising from post-renal transplant or xenoperfusion.

### Claim 70 (depends on 35)

A process of preparing the compound of claim 35 comprising the steps of:
i) reacting a compound having the structure
52
wherein R1, R3 and R4 are as defined in claim 35,
with trifluoromethanesulfonic anhydride under inert conditions to form a triflate; and
ii) reacting the triflate of step i) with a nucleophilic reagent in a polar-aprotic solvent to substitute the triflate with the nucleophile and to form the compound.

### Claim 71 (depends on 70)

The process of claim 70, wherein the nucleophilic reagent is sodium acetate, sodium phenylacetate, sodium azide, tetrabutylammonium fluoride hydrate, or tetrabutylammonium chloride.

### Claim 72 (depends on 70)

The process of claim 70, wherein the polar-aprotic solvent is dichloromethane, pyridine, dimethylformamide, methylsulfoxide, or acetonitrile.

### Claim 73 (depends on 71)

The process of claim 71, wherein the nucleophilic reagent is sodium acetate or sodium phenylacetate, further comprising hydrolyzing the product of step ii) in the presence of 1N hydrochloric acid.

### Claim 74 (depends on 71)

The process of claim 71, wherein the nucleophilic reagent is sodium azide, further comprising reacting the product of step ii) with hydrogen in the presence of palladium and carbon in methanol or ethanol.

### Claim 75 (depends on 71)

The process of claim 71, wherein the nucleophile is tetrabutylammonium fluoride hydrate, further comprising reacting the product of step ii) with benzyl chloride.

### Claim 76

A process of forming a secondary amine compound from an azide of the compound by contacting the azide of the compound with hydrogen, palladium and carbon in a polar-protic solvent.

### Claim 77 (depends on 76)

The process of claim 76, wherein the polar-protic solvent is an alcohol.

### Claim 78 (depends on 1, 76)

The process of claim 76, wherein the, secondary amine compound has the structure:
53
wherein R1, R3 and R4 are as defined in claim 1 and R9 is an alkyl group,
and wherein the azide of the compound has the structure:
54

### Claim 79 (depends on 78)

The process of claim 78, wherein the polar-protic solvent is an alcohol.

### Claim 80 (depends on 79)

The process of claim 79, wherein the alcohol is CH3OH and R9 is CH3.

### Claim 81 (depends on 79)

The process of claim 79, wherein the alcohol is CH3CH2OH and R9 is CH3CH2.

### Claim 82 (depends on 1)

A process for detecting the binding of the compound of claim 1 to a target, comprising contacting the compound with the target and detecting the binding of the compound to the target.

### Claim 83 (depends on 82)

The process of claim 82, wherein the target is a DNA.

### Claim 84 (depends on 82)

The process of claim 82, wherein the target is a receptor.

### Claim 85 (depends on 82)

The process of claim 82, wherein the target is an enzyme.

### Claim 86 (depends on 1)

A process for detecting the localization of a receptor in a subject comprising administering the compound of claim 1 to the subject and detecting at any location in the subject's body to identify a point of accumulation of the compound so as to thereby localize the receptor in the subject, wherein localization of a receptor means a higher concentration of that receptor then at other points in the subject's body.

### Claim 87 (depends on 1)

A process of identifying a target that binds the compound of claim 1, comprising contacting the compound with the target, isolating the target so as to thereby identify the target.

### Claim 88 (depends on 87)

The process of claim 87, wherein the target is a DNA.

### Claim 89 (depends on 87)

The process of claim 87, wherein the target is a receptor.

### Claim 90 (depends on 87)

The process of claim 87, wherein the target is an enzyme.

### Claim 91 (depends on 1)

A process of identifying a receptor that binds the compound of claim 1 in a subject, comprising administering the compound to the subject, imaging the subject's body to identify the point of accumulation of the compound in the subject, and identifying the receptor present at the point of accumulation of the compound, so as to thereby identify the receptor in the subject.
